Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study

Table 3 Total number of patients, years at risk and AEs leading to discontinuation

	July/03-Oct/05	Oct/05-Dec/07
Total number of patients	301	301
Number of AEs resulting in discontinuation	3	44
Number of patient months at risk	20492	9929
Rate of AEs per patient-months-at-risk	0.0001**	0.0044**

AE: adverse event; **Difference between two periods is significant at p < 0.001 level

ISSN: 1471-2474